Data Year:

For its 2024 fiscal year, Twist Bioscience Corp, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
James M. Thorburn
Former Chief Financial Officer
Total Compensation $1,104,914 View details Pay Rank By Title In Biotechnology industry #397 View more
Emily M. Leproust Ph.D.
Chief Executive Officer and Chair of the Board
Total Compensation $7,620,611 View details Pay Rank By Title In Biotechnology industry #165 View more
Patrick Finn Ph.D.
President and Chief Operating Officer
Total Compensation $3,854,551 View details Pay Rank By Title In Biotechnology industry #40 View more
William Banyai Ph.D.
Senior Vice President of Advanced Development and General Manager of Data Storage
Total Compensation $2,328,874 View details Pay Rank By Title In Biotechnology industry #1 View more
Dennis Cho
Chief Legal Officer and Corporate Secretary
Total Compensation $1,798,432 View details Pay Rank By Title In Biotechnology industry #54 View more
Paula Green
Senior Vice President of Human Resources
Total Compensation $2,005,681 View details Pay Rank By Title In Biotechnology industry #3 View more
Adam Laponis
Chief Financial Officer
Total Compensation $5,008,244 View details Pay Rank By Title In Biotechnology industry #60 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at Twist Bioscience Corp as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Twist Bioscience Corp income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Twist Bioscience Corp annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
James M. Thorburn
Former Chief Financial Officer
Total Cash $501,675 Equity $487,484 Other $115,755 $1,104,914
Emily M. Leproust Ph.D.
Chief Executive Officer and Chair of the Board
Total Cash $1,640,575 Equity $5,849,949 Other $130,087 $7,620,611
Patrick Finn Ph.D.
President and Chief Operating Officer
Total Cash $965,000 Equity $2,762,157 Other $127,394 $3,854,551
William Banyai Ph.D.
Senior Vice President of Advanced Development and General Manager of Data Storage
Total Cash $876,208 Equity $1,435,172 Other $17,494 $2,328,874
Dennis Cho
Chief Legal Officer and Corporate Secretary
Total Cash $768,575 Equity $1,021,913 Other $7,944 $1,798,432
Paula Green
Senior Vice President of Human Resources
Total Cash $658,525 Equity $1,229,460 Other $117,696 $2,005,681
Adam Laponis
Chief Financial Officer
Total Cash $806,332 Equity $4,197,600 Other $4,312 $5,008,244
For its 2024 fiscal year, Twist Bioscience Corp, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Emily M. Leproust Ph.D. CEO Pay $7,620,611 Median Employee Pay $208,280 CEO Pay Ratio 37:1
For its 2024 fiscal year, Twist Bioscience Corp, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Jan Johannessen Total Cash $284,981
Keith Crandell Total Cash $272,481
Nelson C. Chan Total Cash $284,981
Robert Chess Total Cash $307,481
Robert Ragusa Total Cash $277,481
Xiaoying Mai Total Cash $269,981
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.